Replidyne, Inc. – Settlement Agreement (November 12th, 2010)
THIS SETTLEMENT AGREEMENT (Agreement) is made and entered into among ev3 Inc., ev3 Endovascular, Inc., (collectively, ev3), FoxHollow Technologies, Inc., (FoxHollow), Tyco Healthcare Group LP d/b/a Covidien (Covidien), Cardiovascular Systems, Inc. (CSI), Aaron Lew (Lew), Paul Tyska (Tyska), Sean Collins (Collins), David Gardner (Gardner), Michael Micheli (Micheli), Kevin Moore (Moore), Steve Pringle (Pringle), Jason Proffitt (Proffitt), Thadd Taylor (Taylor), and Rene Treanor-Sarria (Treanor-Sarria). The above identified persons are referred to collectively as Parties and individually as Party.
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Executive Officer Severance Plan (September 28th, 2010)
Effective June 28, 2010, the Company adopted the Cardiovascular Systems, Inc. Executive Officer Severance Plan. The Severance Plan applies initially to: David L. Martin, President and Chief Executive Officer; Laurence L. Betterley, Chief Financial Officer; James E. Flaherty, Chief Administrative Officer and Secretary; Robert J. Thatcher, Executive Vice President; Brian Doughty, Vice President of Commercial Operations; Paul A. Tyska, Vice President of Business Development; Paul A. Koehn, Vice President of Manufacturing; and Scott W. Kraus, Vice President of Sales. Under the Severance Plan, if the Company terminates an executive without cause or due to a reduction in force, as defined in the plan, the executive will receive certain severance benefits during the severance period. The severance period is 18 months for the Chief Executive Officer; 15 months for the Chief Financial Officer, and 12 months for all other executives. For purposes of the Severance Plan, cause is generally defined
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Fiscal Year 2011 Executive Officer Base Salaries (September 28th, 2010)
The Companys executive officers are scheduled to receive the following annual base salaries for the fiscal year ending June 30, 2011 in their current positions:
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Fiscal Year 2009 Executive Officer Annual Cash Incentive Compensation (May 14th, 2009)
Effective February 25, 2009, the Companys board of directors adopted an executive officer cash incentive compensation plan applicable to the six-month period ended June 30, 2009. This plan conditions the payment of incentive compensation to all participants upon the Companys achievement of revenue and adjusted EBITDA financial goals. Target bonus amounts are split evenly between these two goals. None of the Companys officers is subject to individual goals under this plan. No plan participant will receive a bonus unless the Company achieves certain minimum adjusted EBITDA goals.